Kronos Bio, Inc.

NasdaqGS:KRON Stock Report

Market Cap: US$61.5m

Kronos Bio Future Growth

Future criteria checks 0/6

Kronos Bio's revenue is forecast to decline at 60.8% per annum while its annual earnings are expected to grow at 7.9% per year. EPS is expected to grow by 9.6% per annum.

Key information

7.9%

Earnings growth rate

9.6%

EPS growth rate

Biotechs earnings growth27.2%
Revenue growth rate-60.8%
Future return on equityn/a
Analyst coverage

Low

Last updated24 Jan 2025

Recent future growth updates

Recent updates

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Jun 11
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio: Still Promising But Riskier Following ASCO Update

Jun 05

Kronos Bio: Underestimated Drug Discovery Platform

May 06

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jan 19
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

Aug 21
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Feb 22
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Nov 01
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib

Aug 16

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jul 07
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

Feb 01
We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Mar 03
How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Jan 09
Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Kronos Bio  EPS misses by $4.10

Nov 18

Earnings and Revenue Growth Forecasts

NasdaqGS:KRON - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20254-77N/AN/A1
12/31/20247-81N/AN/A1
9/30/202410-86-78-78N/A
6/30/20248-103-88-88N/A
3/31/20248-116-97-97N/A
12/31/20236-113-79-79N/A
9/30/20234-119-77-76N/A
6/30/20233-120-76-76N/A
3/31/20231-123-74-73N/A
12/31/2022N/A-133-92-91N/A
9/30/2022N/A-164-128-127N/A
6/30/2022N/A-165-127-125N/A
3/31/2022N/A-161-126-122N/A
12/31/2021N/A-151-122-118N/A
9/30/2021N/A-122-82-75N/A
6/30/2021N/A-128-76-65N/A
3/31/2021N/A-108-60-50N/A
12/31/2020N/A-88-47-38N/A
9/30/2020N/A-61-34-27N/A
6/30/2020N/A-25-24-20N/A
3/31/2020N/A-20-22-19N/A
12/31/2019N/A-16-18-15N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: KRON is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: KRON is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: KRON is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: KRON's revenue is expected to decline over the next 3 years (-60.8% per year).

High Growth Revenue: KRON's revenue is forecast to decline over the next 3 years (-60.8% per year).

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if KRON's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/30 11:44
End of Day Share Price 2025/01/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kronos Bio, Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Robert BurnsH.C. Wainwright & Co.
Michael YeeJefferies LLC